## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 12 )\*

	(Americaneric No. 12)				
	CORCEPT THERAPEUTICS, INC.				
	(Name of Issuer)				
Common Stock					
(Title of Class of Securities)					
	218352102				
	(CUSIP Number)				
	12/31/20				
	(Date of Event Which Requires Filing of this Statement)				
	e appropriate box to designate the rule pursuant to which this is filed:				
	/ X / Rule 13d-1(b) / / Rule 13d-1(c) / / Rule 13d-1(d)				
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.					
deemed t Exchange thatsect	rmation required in the remainder of this cover page shall not be o be "filed" for the purpose of Section 18 of the Securities Act of 1934 ("Act") or otherwise subject to the liabilities of ion of the Act but shall be subject to all other provisions of (however, see the Notes).				
form are	who respond to the collection of information contained in this not required to respond unless the form displays a currently (B) control number.				
CUSIP No	. 218352102				
1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only).				
	INGALLS & SNYDER, LLC 13-5156620				
2.	Check the Appropriate Box if a Member of a Group (a)				
	(b)				
3.	SEC Use Only				
4.	Citizenship or Place of Organization				
	New York				

Number of Shares Beneficially Owned by Each Reporting Person With:

	6.	Share	ed Voting Power	0		
	7.		Dispositive Power	0		
	8.		ed Dispositive	7,583,772		
9.		Aggregate	e Amount Beneficially Owned b			
			7,583,772			
10.		Check if the Aggregate Amount in Row (9) Excludes Certain Shares				
			-			
11.	Percent of Class Represented by Amount in Row (9)					
		6.53%	-			
12.		Type of Reporting Person				
	BD,IA					
Item	1.					
		(a)	Name of Issuer			
			CORCEPT THERAPEUTICS, INC.			
		(b)	Address of Issuer's Principa	al Executive Offices		
			149 COMMONWEALTH DRIVI MENLO PARK, CA 94025	3		
Item	2					
100111	_•	(a)	Name of Persons Filing			
			INGALLS & SNYDER, LLC			
		(b)	Address of Principal Busines Residence	ss Office or, if none,		
			1325 AVEUNE OF THE AMERICAS,	, NEW YORK, NY 10019		
		(c)	Citizenship			
			NEW YORK			
		(d)	Title of Class of Securities	5		
			COMMON STOCK			
		(e)	CUSIP Number			
			218352102			
Item	tem 3. This statement is filed pursuant to Rule 13d-1(b), and t Filing is a:					
		(a) [X]		d under section 15 of the Act		
		(e) [X]	(15 U.S.C. 780); An investment adviser in ac section 240.13d-1(b)(1)(ii)			

Ownership Item 4.

(a) Amount beneficially owned: 7,583,772

- (b) Percent of Class: 6.53%
- (c) Number of shares as to which such person has:
  - (i) sole power to vote or to direct the vote:

(ii) shared power to vote or to direct the vote:

(iii) sole power to dispose or to direct the disposition of:

(iv) shared power to dispose or to direct the disposition of:

7,583,772

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the face that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

## INAPPLICABLE

Ownership of More than Five Percent on Behalf of Another Person Item 6.

> Ingalls & Snyder, LLC ("I&S") is a registered broker dealer and a registered investment advisor. Shares reported under shared dispositive power include shares held in accounts managed under investment advisory contracts.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

Not applicable.

Identification and Classification of Members of the Group Ttem 8.

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer ofthe securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

## SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 9, 2021

Date

INGALLS & SNYDER, LLC

By: /s/ Thomas O. Boucher, Jr.

Thomas O. Boucher, Jr. Manager